Is intent-to-treat analysis always (ever) enough? - National Genomics Data Center (CNCB-NGDC)

Advanced Search

Is intent-to-treat analysis always (ever) enough?

Lewis B Sheiner

Author Information

Lewis B Sheiner: Department of Laboratory Medicine, School of Medicine, University of California San Francisco, Box 0626, San Francisco, CA, 94143, USA.

PMID: 12207643 DOI: 10.1046/j.1365-2125.2002.01628.x

No abstract text available.

Stat Methods Med Res. 1999 Sep;8(3):183-93 [PMID: 10636334]
Annu Rev Pharmacol Toxicol. 2000;40:67-95 [PMID: 10836128]
Annu Rev Public Health. 2000;21:121-45 [PMID: 10884949]
N Engl J Med. 1979 May 31;300(22):1242-5 [PMID: 431682]
Epidemiology. 1999 Jan;10(1):37-48 [PMID: 9888278]
Stat Med. 1991 Jan;10(1):45-52 [PMID: 2006355]
Stat Med. 1991 Oct;10(10):1595-605 [PMID: 1947515]
Clin Pharmacokinet. 1994 Sep;27(3):202-15 [PMID: 7988102]
Clin Pharmacol Ther. 1995 Jan;57(1):6-15 [PMID: 7828382]
Stat Med. 1990 Jun;9(6):645-56 [PMID: 2218168]

Clinical Trials as Topic

Humans

Patient Compliance

Patient Dropouts

Research Design

Journal Article Review

Intent-to-treat analysis.Intent-to-treat analysis.Is 50% ever enough?Is "thank you" ever enough?Embryo research: is disclosing commercial intent enough?[Intent to treat].Intent-to-treat.Blood transfusions: is "safest ever" safe enough?Is science ever enough? Dare to play politics.Is it ever enough to die of old age?

The Importance of Estimating Causal Effects for Evaluating a Nicotine Standard for Cigarettes.Variations in study outcomes relative to intention-to-treat and per-protocol data analysis techniques in the evaluation of efficacy for treatment of venous leg ulcers with dehydrated human amnion/chorion membrane allograft.Intention-to-treat concept: A review.Incremental patient care program decreases anxiety, reduces depression and improves the quality of life in patients with colorectal cancer receiving adjuvant chemotherapy.Substance-use outcomes at 18 months past baseline: the PROSPER Community-University Partnership Trial.Trends in the crossover of patients in phase III oncology clinical trials in the USA.Preventing substance misuse through community-university partnerships: randomized controlled trial outcomes 4½ years past baseline.A non-parametric Bayesian approach for adjusting partial compliance in sequential decision making.Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC).An introduction to causal inference for pharmacometricians.

See all "Cited by" articles